Autoimmune & Rheumatology Clinical Trials Update: Week 13, 2026

Published March 29, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis

This Phase 3 trial is studying different biologic medications given one after another to children with polyarticular course juvenile idiopathic arthritis (JIA) who did not improve with their first TNFi treatment. The goal is to find better ways to control the disease and reduce joint pain and swelling in young patients who do not respond to standard therapies. The study is recruiting about 400 children in the United States and Germany, making it one of the largest efforts to improve treatment strategies for this group.

Open Label Treprostinil Raynaud's Study

This study is testing an oral medication called treprostinil for people with severe Raynaud's phenomenon, a condition that causes painful fingers and toes due to poor blood flow. Many patients do not improve with current treatments, so this trial could provide a new option that helps increase blood flow and ease symptoms. The trial is currently recruiting adults in the United States with both primary and secondary forms of Raynaud's.

Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs

This upcoming Phase 4 trial will investigate whether briefly stopping methotrexate, a common medication for autoimmune rheumatic diseases, can improve the body’s immune response to the PCV-20 vaccine. Better vaccine response could mean stronger protection against infections for patients taking methotrexate. The study plans to enroll 192 adults but has not started recruiting yet.

Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis

This Phase 2 study has evaluated the long-term safety of tofacitinib, an oral medication for children with juvenile idiopathic arthritis. Knowing the safety of tofacitinib over time helps doctors and families understand if it can be a reliable treatment option for managing symptoms. The trial has completed and included many international participants who previously used this medication.

Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT)

This Phase 2 trial tested baricitinib combined with corticosteroids in children newly diagnosed with juvenile dermatomyositis, a rare inflammatory muscle disease. If baricitinib proves effective, it could offer a safer and better treatment option than current therapies. The study completed in France with 16 participants, and the results are awaited.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.